Instant hydrogel formation of terpyridine-based complexes triggered by DNA via non-covalent interaction

Nanoscale ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 4044-4052 ◽  
Author(s):  
Lijun Geng ◽  
Xudong Yu ◽  
Yajuan Li ◽  
Yanqiu Wang ◽  
Yongquan Wu ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Drug Release ◽  
Controlled Drug Release ◽  
Covalent Interaction ◽  
Wide Range ◽  
Hydrogel Formation ◽  
Potential Use

Biomolecule-based hydrogels have potential use in a wide range of applications such as controlled drug release, tissue engineering, and biofabrication.

scholarly journals Controlled drug release for tissue engineering

2015 ◽  
Vol 219 ◽  
pp. 119-128 ◽  
Author(s):  
Kunal J. Rambhia ◽  
Peter X. Ma
Keyword(s):  
Tissue Engineering ◽  
Drug Release ◽  
Controlled Drug Release

Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design

2017 ◽  
Vol 23 (3) ◽  
pp. 362-372 ◽  
Author(s):  
Abdelbary Elhissi
Keyword(s):  
Clinical Trials ◽  
Drug Release ◽  
Controlled Drug Release ◽  
Drug Carriers ◽  
Device Design ◽  
Inhalation Device ◽  
Liposome Preparation ◽  
Wide Range ◽  
Therapeutic Molecules

Liposomes are established drug carriers for inhalation owing to their safety and ability to provide controlled drug release in the lung. These carriers can entrap a wide range of therapeutic molecules for delivery in large volumes to the peripheral airways using medical nebulizers. Pressurized metered inhalers (pMDIs), soft mist inhalers (SMIs) and dry powder inhalers (DPIs) can deliver relatively small quantities of medication to the lung when compared to medical nebulizers which can deliver large volumes using simple liposome preparation techniques. Unfortunately, the shearing provided during nebulization to convert the aqueous liposome dispersions into “respirable” aerosol droplets may exert physical stress on liposome bilayers, causing losses of the originally entrapped drug. The development of successful liposome carriers for inhalation depends on two main factors which are formulation composition and nebulizer design, with the aim of reducing the detrimental effect of shearing on liposome stability and maximizing the deposition of vesicles in the ‘deep lung’. A number of nebulizable liposome formulations have reached clinical trials. For example, Arikace® (liposomal amikacin) and Pulmaquin® (liposomal ciprofloxacin) are antibacterial formulations currently in advanced stages of development. In this review, the role of liposome formulation and inhalation device design on the suitability of liposomes for eliciting controlled drug release in the lung was evaluated. Moreover, the factors contributing to the success of Arikace® in clinical trials were appraised.

scholarly journals Polyelectrolyte Complex Based Nanocapsules Carrying Novel 5-Nitroindazole Thiazolidines with Potential Use in Treating Oral Infections

2017 ◽  
Vol 54 (1) ◽  
pp. 160-167
Author(s):  
Toni Andor Cigu ◽  
Mihaela Nicoleta Holban ◽  
Anca Niculina Cadinoiu ◽  
Valeriu Sunel ◽  
Catalina Lionte ◽  
...  
Keyword(s):  
Drug Release ◽  
Salmonella Enteritidis ◽  
Controlled Drug Release ◽  
Bacterial Strains ◽  
Oral Infections ◽  
Chemical Structures ◽  
Particle Stability ◽  
Eudragit E100 ◽  
And Staphylococcus Aureus ◽  
Potential Use

The aim of this research was the synthesis of novel 2,3-disubstituted 1,3 thiazolidines, derived from 5-nitroindazole with antimicrobial activity and their encapsulation into polymer nanocapsules. Starting from previously synthesised hydrazones, there have been obtained novel thiazolidines by reaction with thioglycolic acid. The envisaged chemical structures were confirmed by spectral and elemental analysis. Two of the obtained thiazolidines were encapsulated into cationic Eudragit E100 nanocapsules, obtained by nanoprecipitation. In order to enhance drug release characteristics and particle stability, Eudragit E100 nanocapsules were covered with anionic polysaccharide (sodium alginate), thus forming a complex polyelectrolyte based membrane. The obtained nanocapsules presented a slower and more controlled drug release. The synthesized active principles, in free state and encapsulated into polymer nanocapsules, were tested for their acute toxicity and their influence on the development of model bacterial strains (Staphylococcus mutans, Actinobacillus actinomycetemcomitans, Bacillus subtilis, Bacillus cereus, Salmonella enteritidis, Escherichia coli and Staphylococcus aureus).

Biomedical applications of polymers 2001 - 2002

e-Polymers ◽  
2003 ◽  
Vol 3 (1) ◽  
Author(s):  
Joseph Jagur-Grodzinski
Keyword(s):  
Tissue Engineering ◽  
Gene Therapy ◽  
Gene Delivery ◽  
Drug Release ◽  
Wound Dressing ◽  
Biomedical Applications ◽  
Bone Repair ◽  
Controlled Drug Release ◽  
Artificial Organs ◽  
Drug And Gene Delivery

Abstract Papers published during 2001 - 2002 on the synthesis and preparation of polymers and polymer-based devices and their applications are reviewed. Polymers for drug and gene delivery, gene therapy, controlled drug release, conjugation with peptides, proteins, and nucleotides, tissue engineering, bone repair and regeneration, coatings, wound dressing, artificial skin and other artificial organs are discussed.

Sign in / Sign up

Export Citation Format

Share Document